San Francisco, California
Cancer biologic therapy trials in San Francisco, CA
37 cancer biologic therapy studies are recruiting participants at sites in San Francisco as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
San Francisco at a glance
- 37 studies are recruiting at a site in San Francisco.
- By phase: Phase 1 (5), Phase 2 (9), Phase 2/3 (2), Phase 3 (21).
- By sponsor: industry (15), university, hospital or other (14), government (8).
- By research area: Lymphoma (11), Lung Cancer (10), Breast Cancer (7), Melanoma (5), Pancreatic Cancer (2), Prostate Cancer (2).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in San Francisco
Basic details from each study's public record (the 30 most recently updated of 37). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Kaiser Permanente - San Francisco ( Site 0080)
- Registry record
- NCT06393374 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016)
- Registry record
- NCT06841354 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- California Pacific Medical Center-Pacific Campus
- Registry record
- NCT06058377 · updated
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Kaiser Permanente-San Francisco
- Registry record
- NCT06876714 · updated
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Phase 3
- Ages 18 to 100
- All sexes
- Sponsor
- Greenwich LifeSciences, Inc.
- Study site
- University of California San Francisco - Helen Diller Family Comprehensive Cancer Center
- Registry record
- NCT05232916 · updated
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Kaiser Permanente-San Francisco · Zuckerberg San Francisco General Hospital
- Registry record
- NCT05812807 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.
Lung cancer studies recruiting in San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Kaiser Permanente-San Francisco
- Registry record
- NCT06498635 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- UCSF Medical Center at Mission Bay ( Site 0178)
- Registry record
- NCT06623422 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- California Pacific Medical Center-Pacific Campus · Kaiser Permanente-San Francisco
- Registry record
- NCT04267848 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- San Francisco Oncology Associates ( Site 0066)
- Registry record
- NCT06312137 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Kaiser Permanente-San Francisco
- Registry record
- NCT04181060 · updated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Phase 2
- From 18 minutes
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- California Pacific Medical Center-Pacific Campus · Kaiser Permanente-San Francisco
- Registry record
- NCT06031688 · updated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- California Pacific Medical Center-Pacific Campus
- Registry record
- NCT06116682 · updated
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Kaiser Permanente-San Francisco · Veterans Affairs Medical Center - San Francisco
- Registry record
- NCT06616584 · updated
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study site
- California Pacific Medical Center-Pacific Campus
- Registry record
- NCT05624996 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.
Prostate cancer studies recruiting in San Francisco
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- San Francisco VA Medical Center
- Registry record
- NCT07164443 · updated
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1
- Ages 18 to 100
- Male participants
- Sponsor
- Janux Therapeutics
- Study site
- UCSF Helen Diller Family Comprehensive Cancer Center
- Registry record
- NCT05519449 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.
Melanoma studies recruiting in San Francisco
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Outpace Bio, Inc.
- Study site
- UCSF - Helen Diller Family Comprehensive Cancer Center
- Registry record
- NCT07664735 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- UCSF Helen Diller Family Comprehensive Cancer Center
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in San Francisco, CA on ClinicalTrials.gov.
Lymphoma studies recruiting in San Francisco
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCSF Medical Center-Mission Bay
- Registry record
- NCT06317662 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Pacific Hematology Oncology Associates ( Site 0131)
- Registry record
- NCT06717347 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCSF Medical Center-Mission Bay
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Kaiser Permanente-San Francisco
- Registry record
- NCT05675410 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Kaiser Permanente-San Francisco
- Registry record
- NCT03150693 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study site
- University of California, San Francisco
- Registry record
- NCT06500273 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCSF Medical Center-Mission Bay
- Registry record
- NCT06124157 · updated
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- C. Babis Andreadis
- Study site
- University of California, San Francisco
- Registry record
- NCT04545762 · updated
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- UCSF Medical Center-Parnassus
- Registry record
- NCT05633615 · updated
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- University of California, San Francisco
- Study site
- University of California, San Francisco
- Registry record
- NCT06252675 · updated
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Phase 3
- From 365 days, up to 25 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- UCSF Medical Center-Mission Bay
- Registry record
- NCT03959085 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in San Francisco, CA on ClinicalTrials.gov.
Ask about studies near San Francisco
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in California
All California locations
185 studies recruiting across 108 cities.
Duarte
77 studies recruiting.
Los Angeles
73 studies recruiting.
Sacramento
36 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections